Modality
Cell Therapy
MOA
TYK2i
Target
AuroraA
Pathway
Fibrosis
NarcolepsyBCCSLE
Development Pipeline
Preclinical
~May 2017
→ ~Aug 2018
Phase 1
~Nov 2018
→ ~Feb 2020
Phase 2
May 2020
→ May 2030
Phase 2Current
NCT06733735
2,440 pts·SLE
2020-05→2030-05·Not yet recruiting
2,440 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-10-096mo agoOrphan Drug· Narcolepsy
2030-05-214.1y awayPh3 Readout· SLE
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2/3
Not yet…
Catalysts
Orphan Drug
2025-10-09 · 6mo ago
Narcolepsy
Ph3 Readout
2030-05-21 · 4.1y away
SLE
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06733735 | Phase 2/3 | SLE | Not yet recr... | 2440 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Sotorapivir | Moderna | Approved | FLT3 |